Philip Budge is an Infectious Disease physician affiliated with Washington University in St. Louis. OpenAlex indexes 48 publications with 1,024 citations (h-index 18); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
620 S Taylor Ave
Div Im Infectious Disease, Ste 100
Saint Louis, MO 631101035
Telephone
314-362-9098Registry record last updated 15 Apr 2025.
Clinical trials
- Moxidectin for LF, Cote d'Ivoire (DOLF)
Sponsor: Washington University School of Medicine
- Spontaneous Antigenemia in Loiasis
Sponsor: Washington University School of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20244 payments
- ABBVIE INC.Program year20241 payment
- Alexion Pharmaceuticals, Inc.Program year20222 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2016–2022 per NIH RePORTER. The latest:
- IMPROVED ANTIGEN DETECTION TESTS FOR FILARIAL INFECTIONS
Washington University
FY2020$173,179K08AI121422
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Moxidectin combination therapies for lymphatic filariasis: an open-label, observer-masked, randomised controlled trial
The Lancet Infectious Diseases
2025 - Moxidectin combination therapies for lymphatic filariasis—36-month follow-up
The Lancet Infectious Diseases
2025 - Wb5, a novel biomarker for monitoring efficacy and success of mass drug administration programs for Wuchereria bancrofti elimination
PLoS neglected tropical diseases
2025 - Adherence to Hygiene Protocols and Doxycycline Therapy in Ameliorating Lymphatic Filariasis Morbidity in an Endemic Area Post-Interruption of Disease Transmission in Ghana
American Journal of Tropical Medicine and Hygiene
2024 - A novel antigen biomarker for detection of high-level of Loa loa microfilaremia
PLoS neglected tropical diseases
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”